Clinical detection of plasma concentration of imipenem cilastatin sodium based on fluorescent probe molecules

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078079

Enrollment

Unknown

Registered

2023-11-28

Start date

2023-12-01

Completion date

Unknown

Last updated

2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Interventions

Infection group (HPLC, fluorescent probe):None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Admission to ICU, aged 18 years or older 2. Application of imipenem cilastatin sodium 3.Voluntary signing of informed consent form

Exclusion criteria

Exclusion criteria: Patients whose blood drug concentration detection is affected by various reasons

Design outcomes

Primary

Measure	Time frame
Imipenem cilastatin blood concentration;Imipenem cilastatin blood concentration;Imipenem cilastatin blood concentration;Imipenem cilastatin blood concentration;	—

Countries

China

Contacts

Public ContactYanfei Mao, Rongrong Ren

1655 Kongjiang Road, Yangpu District, Shanghai

maoyanfei@xinhuamed.com.cn+86 21 2507 7825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026